NDAINTRAVENOUSINJECTABLE
Approved
Aug 2007
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
AMMONIA N 13 (nh3n13) by Medica Corp is radiopharmaceutical activity [moa]. First approved in 2007.
Drug data last refreshed 2h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Ammonia N 13 is a radioactive diagnostic agent administered intravenously for PET imaging applications. It functions as a radiopharmaceutical that leverages N-13 decay to enable visualization of cardiac and pulmonary perfusion. This agent is used to assess regional blood flow and metabolic activity in diagnostic imaging protocols.
LOE Approaching
Product is approaching loss of exclusivity with moderate competitive pressure (30%), suggesting declining team size and transition focus toward generic competition management.
Mechanism of Action
Radiopharmaceutical Activity
Pharmacologic Class:
Radioactive Diagnostic Agent
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Ammonia N 13 roles focus on maintaining diagnostic utility in specialized imaging centers and managing the transition toward generic competition. Career opportunities are limited by the product's mature lifecycle stage and approaching LOE, making this a maintenance-focused position rather than growth-oriented.
Medical Affairs Lead
Worked on AMMONIA N 13 at Medica Corp? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.